A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ�38518168 in Subjects with Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy

The primary objective is to assess the efficacy (as measured by the reduction of the signs and symptoms of RA) of JNJ-38518168-ZBQ at doses of 3, 10, and 30 mg/d compared with placebo in subjects with active RA despite concomitant MTX therapy.